Microbiota and innate immunity in intestinal inflammation and neoplasia

Current Opinion in Gastroenterology

Volumn 29, Issue 1, 2013, Pages 85-91

  Cario, Elke ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

carcinogenesis; colitis; inflammatory bowel diseases; intestinal epithelium; STAT3

Indexed keywords

INFLAMMASOME; MUCIN 2; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; OXIDOREDUCTASE; REACTIVE OXYGEN METABOLITE; SPERMINE OXIDASE; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

BACTEROIDES FRAGILIS; COLON CANCER; COLORECTAL CARCINOMA; COMMENSAL; DISEASE ASSOCIATION; DNA DAMAGE; ENTERITIS; ENTEROTOXIGENIC BACTEROIDES FRAGILIS; FUSOBACTERIUM NUCLEATUM; GENETIC VARIABILITY; HELICOBACTER PYLORI; IMMUNOSURVEILLANCE; INNATE IMMUNITY; INTESTINE CANCER; INTESTINE FLORA; MICROBIOME; MUTATION; NONHUMAN; PATHOGENESIS; PROTEIN SECRETION; REVIEW;

ENTEROCOLITIS; HUMANS; IMMUNITY, INNATE; INTESTINAL NEOPLASMS; METAGENOME; MICROBIAL INTERACTIONS; SIGNAL TRANSDUCTION;

EID: 84871634362     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32835a670e     Document Type: Review

References (57)

1. Abraham C, Medzhitov R. Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology 2011; 140:1729-1737.
2. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011; 474:307-317.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-674.
4. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012; 10:639-645.
5. McLean MH, Murray GI, Stewart KN, et al. The inflammatory microenvironment in colorectal neoplasia. PLoS One 2011; 6:e15366.
6. Kuraishy A, Karin M, Grivennikov SI. Tumor promotion via injury and deathinduced inflammation. Immunity 2011; 35:467-477.
7. Sartor RB. Genetics and environmental interactions shape the intestinal microbiome to promote inflammatory bowel disease versus mucosal homeostasis. Gastroenterology 2010; 139:1816-1819.
8. Elson CO, Cong Y. Host-microbiota interactions in inflammatory bowel disease. Gut Microbes 2012; 3:332-344.
9. Honda K, Littman DR. The microbiome in infectious disease and inflammation. Annu Rev Immunol 2012; 30:759-795.
10. Sobhani I, Tap J, Roudot-Thoraval F, et al. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One 2011; 6:e16393.
11. Marchesi JR, Dutilh BE, Hall N, et al. Towards the human colorectal cancer microbiome. PLoS One 2011; 6:e20447.
12. Kostic AD, Gevers D, Pedamallu CS, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 2012; 22:292-298.
13. Castellarin M, Warren RL, Freeman JD, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 2012; 22:299-306.
14. Dharmani P, Strauss J, Ambrose C, et al. Fusobacterium nucleatum infection of colonic cells stimulates MUC2 mucin and tumor necrosis factor alpha. Infect Immun 2011; 79:2597-2607.
15. Strauss J, Kaplan GG, Beck PL, et al. Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis 2011; 17:1971-1978.
16. Wu S, Rhee KJ, Albesiano E, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009; 15:1016-1022.
17. Goodwin AC, Destefano Shields CE, Wu S, et al. Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. Proc Natl Acad Sci U S A 2011; 108:15354-15359.
18. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature 2011; 473:174-180.
19. Project THM. Structure, function and diversity of the healthy human microbiome. Nature 2012; 486:207-214.
20. Human Microbiome Project Consortium. A framework for human microbiome research. Nature 2012; 486:215-221.
21. Project THM. The Human Microbiome Project Collection. 2012. www.ploscollections. org/hmp
22. Kau AL, Ahern PP, Griffin NW, et al. Human nutrition, the gut microbiome and the immune system. Nature 2011; 474:327-336.
23. Kane M, Case LK, Kopaskie K, et al. Successful transmission of a retrovirus depends on the commensal microbiota. Science 2011; 334:245-249.
24. Kuss SK, Best GT, Etheredge CA, et al. Intestinal microbiota promote enteric virus replication and systemic pathogenesis. Science 2011; 334:249-252.
25. Minot S, Sinha R, Chen J, et al. The human gut virome: inter-individual variation and dynamic response to diet. Genome Res 2011; 21:1616-1625.
26. Minot S, Grunberg S, Wu GD, et al. Hypervariable loci in the human gut virome. Proc Natl Acad Sci U S A 2012; 109:3962-3966.
27. Podolsky DK, Gerken G, Eyking A, Cario E. Colitis-associated variant of TLR2 causes impaired mucosal repair because of TFF3 deficiency. Gastroenterology 2009; 137:209-220.
28. Vaishnava S, Yamamoto M, Severson KM, et al. The antibacterial lectin RegIIIgamma promotes the spatial segregation of microbiota and host in the intestine. Science 2011; 334:255-258.
29. Biswas A, Petnicki-Ocwieja T, Kobayashi KS. Nod2: a key regulator linking microbiota to intestinal mucosal immunity. J Mol Med (Berl) 2012; 90:15-24.
30. Johansson ME, Larsson JM, Hansson GC. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of hostmicrobial interactions. Proc Natl Acad Sci U S A 2011; 108 (Suppl 1):4659-4665.
31. Fu J, Wei B, Wen T, et al. Loss of intestinal core 1-derived O-glycans causes spontaneous colitis in mice. J Clin Invest 2011; 121:1657-1666.
32. Cario E. Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm Bowel Dis 2010; 16:1583-1597.
33. Cario E. Innate immune signalling at intestinal mucosal surfaces: a fine line between host protection and destruction. Curr Opin Gastroenterol 2008; 24:725-732.
34. Gross O, Thomas CJ, Guarda G, Tschopp J. The inflammasome: an integrated view. Immunol Rev 2011; 243:136-151.
35. Werts C, Rubino S, Ling A, et al. Nod-like receptors in intestinal homeostasis, inflammation, and cancer. J Leukoc Biol 2011; 90:471-482.
36. Salcedo R, Worschech A, Cardone M, et al. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med 2010; 207:1625-1636.
37. Allen IC, TeKippe EM, Woodford RM, et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med 2010; 207:1045-1056.
38. Zaki MH, Boyd KL, Vogel P, et al. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 2010; 32:379-391.
39. Dupaul-Chicoine J, Yeretssian G, Doiron K, et al. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity 2010; 32:367-378.
40. Hu B, Elinav E, Huber S, et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci U S A 2010; 107:21635-21640.
41. Zaki MH, Vogel P, Malireddi RK, et al. The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. Cancer Cell 2011; 20:649-660.
42. Allen IC, Wilson JE, Schneider M, et al. NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-kappaB signaling. Immunity 2012; 36:742-754.
43. Elinav E, Strowig T, Kau AL, et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011; 145:745-757.
44. Normand S, Delanoye-Crespin A, Bressenot A, et al. Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury. Proc Natl Acad Sci U S A 2011; 108:9601-9606.
45. Chen GY, Liu M, Wang F, et al. A functional role for Nlrp6 in intestinal inflammation and tumorigenesis. J Immunol 2011; 186:7187-7194.
46. Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 2007; 317:124-127. (Pubitemid 47056471)
47. Lee SH, Hu LL, Gonzalez-Navajas J, et al. ERK activation drives intestinal tumorigenesis in Apc(min/) mice. Nat Med 2010; 16:665-670.
48. Schiechl G, Bauer B, Fuss I, et al. Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80CD11b(high) Gr1(low) macrophages. J Clin Invest 2011; 121:1692-1708.
49. Fukata M, Chen A, Vamadevan AS, et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 2007; 133:1869-1881.
50. Fukata M, Shang L, Santaolalla R, et al. Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitisassociated tumorigenesis. Inflamm Bowel Dis 2011; 17:1464-1473.
51. Lowe EL, Crother TR, Rabizadeh S, et al. Toll-like receptor 2 signaling protects mice from tumor development in a mouse model of colitis-induced cancer. PLoS One 2010; 5:e13027.
52. Hold GL, Rabkin CS, Chow WH, et al. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 2007; 132:905-912. (Pubitemid 46440859)
53. De Jager PL, Franchimont D, Waliszewska A, et al. The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun 2007; 8:387-397. (Pubitemid 47163102)
54. Figueroa L, Xiong Y, Song C, et al. The Asp299Gly polymorphism alters TLR4 signaling by interfering with recruitment of MyD88 and TRIF. J Immunol 2012; 188:4506-4515.
55. Eyking A, Ey B, Runzi M, et al. Toll-like receptor 4 variant D299G induces features of neoplastic progression in Caco-2 intestinal cells and is associated with advanced human colon cancer. Gastroenterology 2011; 141:2154-2165.
56. Frank DN, Zhu W, Sartor RB, Li E. Investigating the biological and clinical significance of human dysbioses. Trends Microbiol 2011; 19:427-434.
57. Azcarate-Peril MA, Sikes M, Bruno-Barcena JM. The intestinal microbiota, gastrointestinal environment and colorectal cancer: a putative role for probiotics in prevention of colorectal cancer? Am J Physiol Gastrointest Liver Physiol 2011; 301:G401-424.